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Sjögren syndrome complicated by
mucosa-associated lymphoid tissue
lymphoma and lymphocytic
interstitial pneumonia
Fatma Ahmed, Osama Raslan, Razi Muzaffar, Nadeem Parkar, Nitin Marwaha and
Medhat M. Osman*
Saint Louis Univeristy, Saint Louis, MO, USA
Sjögren syndrome (SS) is an autoimmune disease with exocrine glands dysfunction
and multiorgan involvement. It is associated with increased risk of lymphoprolifer-
ative disorders, especially B-cell marginal zone lymphoma. While the role of F-18
Fluorodeoxyglucose position emission tomography/computed tomography (F-18 FDG
PET/CT) for evaluation of lymphoma has been established, its use in patients with a
chronic history of SS to evaluate for possible lymphoproliferative disorders or multiorgan
involvement is limited. We present a case of chronic SS in which F-18 FDG PET/CT
demonstrated FDG avid intraparotid and cervical lymph nodes pathologically proven to
be mucosa-associated lymphoid tissue lymphoma. In addition, the patient had bibasilar
cystic changes consistent with lymphocytic interstitial pneumonia.
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Introduction
F-18 Fluorodeoxyglucose position emission tomography/computed tomography (F-18 FDG
PET/CT) plays an important role in the evaluation of lymphoma. Patients with chronic Sjögren
syndrome (SS) are at risk of lymphoproliferative disorders, particularly B-cell marginal zone
lymphoma. There are limited publications on the role of F-18 FDG PET/CT in evaluating these
patients for possible development of lymphoma or multiorgan involvement with only a few cases
reported.Wepresent a patientwith a 15-year history of SS inwhich F-18 FDGPET/CTdemonstrated
hypermetabolic intraparotid and cervical lymph nodes pathologically proven to be lymphoma. In
addition, there were bibasilar cystic changes in the lungs consistent with lymphocytic interstitial
pneumonia (LIP).
Background
A 51-year-old female with a history of SS diagnosed 15 years ago presented with a mass on her left
face. Contrast-enhanced computed tomography (CCT) demonstrated fatty atrophy of the parotid
glands (Figure 1, yellow arrow), predominately enhancing left parotid nodule (Figure 1, green
arrow), and enlarged left cervical lymph nodes (Figure 1, red arrows). Diagnostic considerations
included chronic sialadenitis but lymphoma or lymphoproliferative disorder was not excluded. F-18
FDG PET/CT demonstrated an FDG avid left parotid nodule with SUV Max 8.6 (Figure 2, green
arrows) and cervical lymph nodes (Figure 2, red arrows), which were suspicious for lymphoma.
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FIGURE 1 | Contrast-enhanced computed tomography demonstrated
fatty atrophy of the parotid glands (yellow arrow), enhancing
predominately left parotid nodule (green arrow), and enlarged cervical
lymph nodes (red arrows).
FIGURE 2 | F-18 Fluorodeoxyglucose position emission tomography/computed tomography demonstrated FDG avid predominately left parotid
nodule (green arrows) and cervical lymph nodes (red arrows), suspicious for lymphoma.
FIGURE 3 | F-18 Fluorodeoxyglucose position emission tomography/computed tomography demonstrated bibasilar thin-walled lung cysts,
consistent with LIP (blue arrowheads).
Other considerations of FDG lesions in the salivary glands may
include salivary gland tumors or lymph node metastases from
squamous cell carcinoma although these would be less likely
in this particular patient. In addition, CT lung window of the
F-18 FDG PET/CT showed non-FDG avid bibasilar thin-walled
lung cysts, consistent with LIP (Figure 3, blue arrowheads). CT
guided fine needle aspiration of the left parotid gland nod-
ule demonstrated medium to intermediate size atypical lym-
phocytes. The atypical lymphocytes were found to be positive
for PAX5 and negative for CD3, CD10, and CD5 with kappa
restriction on flow cytometric analysis. On histological evalu-
ation, a lymphoepithelial lesion with atypical lymphocytes of
above mentioned immunophenotype is noted and a diagnosis
of extranodal marginal zone lymphoma of mucosa-associated
lymphoid tissue (MALT lymphoma) was rendered (Figure 4).
This case demonstrates SS-associated LIP complicated by MALT
lymphoma. The patient would be followedmonthly and treatment
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FIGURE 4 | FNA of left parotid nodule demonstrated monotonous
population of small to intermediated size atypical lymphocytes.
(Top panels – Diff-Quik stain, bottom panels – Pap stain).
options included single agent Rituxan or an immunochemother-
apy regimen, such as bendamustine/rituximab. The patient is
currently receiving hydroxychloroquine therapy for SS and mon-
itoring of lymphoma, also follow-up F-18 FDG PET/CT was
recommended per the oncologist.
Discussion
Sjögren syndrome is an autoimmune condition characterized
by lymphocytic infiltration of exocrine glands and multiorgan
involvement that affects approximately 0.1–3.0% of the general
population (female/male ratio 9:1) (1). SS is complicated by
lymphoproliferative disorders, most commonly B-cell lymphoma,
in 5–10% of patients with two to eight times an increased risk of
death compared to the control population (2).
In patients with SS thoracic involvement, airway disease and
interstitial lung disease (ILD) are common. The most observed
histological patterns are non-specific interstitial pneumonia
(NSIP) and LIP, while usual interstitial pneumonia (UIP) is
less frequent (3). Ryoko et al. described CT findings of diverse
thoracic manifestation of SS with its pathologic correlation.
They divided the pulmonary manifestation into three groups:
interstitial pneumonia, airway abnormalities, and lymphoprolif-
erative disorders (4).
In a recent study, Cohen et al. developed a PET/CT activ-
ity score which integrated PET for the work-up of SS patients
and associated lymphoma to correlate with disease activity. They
found that patients with SS had a significantly higher FDG uptake
in salivary glands, lymph nodes, and lungs compared to control
group. Furthermore, patients who developed lymphoma had an
even higher SUV max than patients without lymphoma. They
concluded F-18 FDG PET/CT could be useful for optimizing
diagnosis, post-therapy evaluation of lymphoma, and multiorgan
involvement in patients with SS. It is especially helpful if combined
with anatomic imaging and minimally invasive techniques for
histological diagnosis (5).
Conclusion
F-18 Fluorodeoxyglucose position emission tomogra-
phy/computed tomography can be useful for optimizing diag-
nosis, post-therapy evaluation of lymphoma, and multiorgan
involvement in patients with SS. It is particularly helpful when
combined with anatomic imaging and minimally invasive
techniques for histological diagnosis (5).
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